Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2023-01-04 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-01-04 English
Director's Dealing 2023
Director's Dealing
2023-01-04 English
Director's Dealing 2023
Director's Dealing
2023-01-04 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. The text includes detailed information about the registration of shares under the 2018 Share Incentive Plan, the 2010 Share Incentive Plan, and the Employee Stock Purchase Plan. It also contains a prospectus for resale of shares by certain stockholders. This type of filing is related to new share issues under employee plans and is not an annual report, earnings release, or other financial report. It is a capital/financing related filing concerning registration of shares for issuance and resale. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement and prospectus, not just an announcement or certification.
2023-01-04 English
Annual Report 2022
Annual Report FY 2022
2023-01-04 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures that shareholders should know about. The text includes a press release about clinical trial results and a presentation, but does not contain detailed financial statements or comprehensive financial analysis. It references the Annual Report on Form 10-K for risk factors but does not itself contain such a report. The document is about a specific event disclosure rather than a full financial report or earnings release. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings like Form 8-K that do not fit other specific categories.
2022-12-08 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.